Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Mustang Bio launches clinical study combining CAR T cells and oncolytic virus to treat glioblastoma

By Brian Buntz | April 13, 2022

Mustang BioThe cell and gene therapy company Mustang Bio (Nasdaq:MBIO) will initiate a Phase 1 clinical trial combining CAR T cells and oncolytic virus as a potential therapy for recurrent glioblastoma.

The prognosis for glioblastoma is generally poor with approximately 40% survival in the first year following diagnosis, according to the American Association of Neurological Surgeons.

The Worcester, Massachusetts–based company made the announcement after reviewing interim data from two ongoing investigator-sponsored Phase 1 clinical studies testing MB-108 (C134 oncolytic virus) and MB‐101 (City of Hope’s IL13Rα2‐targeted CAR T cell therapy).

Mustang Bio recently shared data supporting the safety of administering MB-108 and MB-101 sequentially in a regimen designated as MB-109 at the American Association for Cancer Research (AACR) Annual Meeting 2022.

“The data presented at the AACR Annual Meeting support the initiation of a Phase 1 clinical trial to evaluate combining locoregional delivery of MB-108 and MB-101 as an attractive strategy for improving outcomes for patients with rGBM,” said Christine Brown, the Heritage Provider Network Professor in Immunotherapy at City of Hope, a not-for-profit clinical research and treatment organization.

“We are excited to build on the interim clinical safety and feasibility data for administering either single agent, MB-101 or MB-108, as well as to take advantage of the potential of oncolytic viral therapy to make the tumor immunologically ’hot’ since clinical data suggest that CAR T cells may be more effective in an inflamed tumor microenvironment,” said Brown in a press release.

In mid-day trading, MBIO shares fell 0.058 to $0.86.

 


Filed Under: Oncology
Tagged With: glioblastoma, MB-108, MB‐101, Mustang Bio, recurrent glioblastoma
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Novartis in the Pharma 50
Novartis announces tislelizumab helped extend median overall survival in first-line advanced esophageal cancer 
Johnson & Johnson Janssen pharmaceutical business in the Pharma 50
Janssen gets positive CHMP opinion for Imbruvica for adults with untreated chronic lymphocytic leukemia
oncopeptides
Oncopeptides’ Pepaxti wins positive opinion from CHMP for multiple myeloma patients
DNA sequencer
Localizing next-generation sequencing testing for cancer patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50